NEW YORK (GenomeWeb) – Rheumatology and autoimmune diagnostics firm Exagen Diagnostics has raised $3.95 million, it said in a regulatory document on Monday.
A spokesperson for the Vista, Calif.-based firm declined to comment, and Exagen did not name the investors in the financing round or say how proceeds would be used. According to a document filed with the US Securities and Exchange Commission, the type of securities offered included debt, and securities to be acquired upon the exercise of an option, warrant, or other right to acquire security.
In the fall, Exagen said in an SEC document that it raised $5 million.
According to its website, the company offers testing services sold under the brand name Avise and using the company's cell-bound complement activation products (CB-CAPS) technology. CB-CAPS are hydrolyzed complement activation products that are bound to circulating cells, including erythrocytes, platelets, and B and T lymphocytes.